75
Participants
Start Date
February 28, 2006
Primary Completion Date
April 30, 2009
Study Completion Date
April 30, 2009
Atazanavir
200 mg to 400 mg orally daily
Darunavir
300 mg or 600 mg orally twice daily
Efavirenz
Dosage dependent on participant
Nevirapine
Dosage dependent on participant
Ritonavir
50 mg or 100 mg orally twice daily
Tenofovir disoproxil fumarate
300 mg orally daily
Pharmacokinetic Study
Intensive PK study will occur at least once. This will require a 24-hour inpatient visit.
Nyu Ny Nichd Crs, New York
Jacobi Med. Ctr. Bronx NICHD CRS, The Bronx
SUNY Downstate Med. Ctr., Children's Hosp. at Downstate NICHD CRS, Brooklyn
Univ. of Maryland Baltimore NICHD CRS, Baltimore
Johns Hopkins Univ. Baltimore NICHD CRS, Baltimore
DUMC Ped. CRS, Durham
Pediatric Perinatal HIV Clinical Trials Unit CRS, Miami
Children's Hospital of Michigan NICHD CRS, Detroit
Rush Univ. Cook County Hosp. Chicago NICHD CRS, Chicago
Harbor UCLA Medical Ctr. NICHD CRS, Torrance
Miller Children's Hosp. Long Beach CA NICHD CRS, Long Beach
Usc La Nichd Crs, Alhambra
Seattle Children's Hospital CRS, Seattle
University of California, UC San Diego CRS, La Jolla
Connecticut Children's Med. Ctr., Hartford
Ann & Robert H. Lurie Children's Hospital of Chicago (LCH) CRS, Chicago
Children's Hosp. of Boston NICHD CRS, Boston
Baystate Health, Baystate Med. Ctr., Springfield
WNE Maternal Pediatric Adolescent AIDS CRS, Worcester
Rutgers - New Jersey Medical School CRS, Newark
St. Jude Children's Research Hospital CRS, Memphis
University of Puerto Rico Pediatric HIV/AIDS Research Program CRS, San Juan
San Juan City Hosp. PR NICHD CRS, San Juan
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
National Institute of Allergy and Infectious Diseases (NIAID)
NIH